Optimal vaccination preventive policies for COVID-19 Research Report (WHO-SAGE)

Grupo ITSON-CONACyT-UNISON September 18, 2020

1. Introduction

In late December 2019, a new virus's appearance is reported in Wuhan City, Hubei Province, China. Called SARS-CoV2, it is the virus that causes the 2019 coronavirus disease (COVID-19) and that, very quickly since its appearance, has spread throughout much of the world, causing severe problems for health systems of all the countries in which it is present [1]. On March 11, 2020, the World Health Organization declared the epidemic by COVID-19 as a pandemic. Around 118,000 cases at that time, distributed in 114 countries and with around 4,291 deaths [2]. In Latin America, the first detected case of COVID-19 occurred in Brazil on February 26, and in Mexico, the first case was reported on February 27, quickly spreading throughout the country [3, 4].

Various control measures have been implemented in all the countries where the disease is present, with quarantine, isolation, and social distancing being the main ones. Despite the measures that different governments have taken to mitigate the epidemic, it has not been controlled. The number of cases and deaths from the disease continues to increase in many countries of the world. On the other hand, since the new coronavirus's appearance, the international scientific community has been working to understand the nature of the virus. They mainly focus on the spreading mechanisms between individuals, developing vaccines and treatments to reduce the number of infections and fatality cases. To get a clearer understanding of different vaccination strategies and their consequences on the number of infected individuals, mathematical models have taken a leading role. The use of various mathematical tools such as SIR and SEIR models has helped to describe epidemics properties around the globe.

Initially, these models have been used to estimate the basic reproductive number associated with the disease and estimate different parameters involved in its spread, such as contagion rates, incubation periods, and recovery rates. They are also being used to propose and evaluate the effect of various control measures, such as quarantine [4–10].

On the other hand, a widely used tool to propose optimal scenarios for applying vaccines or treatments is the optimal control theory. With this tool, it is possible to find scenarios in which the application of the vaccine minimizes the damage caused by the disease and the cost of its application. Some results

about it have been applied to control other diseases for humans and animals [11-15].

In this work, we present a mathematical model to describe the propagation disease and vaccination dynamics of COVID-19. An analysis of the basic reproductive number is shown, providing conditions, in terms of the vaccination parameters, that allow both reducing the value of \mathcal{R}_0 and lowering its value below one. Finally, optimal scenarios for applying a preventive vaccine are also presented through optimal control theory. It is important to stress that we used the Mexican Ministry of Health data to estimate the proposed model's parameters before the vaccine application. In this way, we have the possibility of analyzing the effect of the vaccine, maintaining a base of values for the model parameters, and thus being able to manipulate only the parameters corresponding to vaccination.

2. Mathematical model formulation

In this section, we formulate our baseline mathematical model, which additionally to the transmission dynamics, includes vaccination. In order to build our model, we follow the classical Kermack-McKendrick approach. Our model splits the population in seven different classes: Susceptible (S), exposed (E), symptomatic infected (I_S) , asymptomatic infected (I_A) , recovered (R), death (D)and vaccinated (V) individuals. It is important to mention that I_S represents the proportion of symptomatic individuals who will later report to some health medical center. Additionally to the classical process an individual might follows during infection, in our model, we assume that reinfection is possible after a period of time. We model the vaccination process considering some assumptions: i) Vaccination is applied to all the alive individuals except those in the symptomatic class. In this situation, vaccines are distributed over individuals on the S, E, I_A , and R classes. ii) The vaccine has preventive nature, that is, only reflected in the susceptible individuals (S). iii) People will only get one vaccine during the campaign. iv) Vaccines do not necessarily have a hundred percent of effectivity, which implies that some vaccinated people can get the disease. We denote the effectivity rate by ϵ . Based on these assumptions our model becomes

$$S'(t) = \mu \bar{N} - \frac{\beta_S I_S + \beta_A I_A}{\bar{N}} S - (\mu + \lambda_V) S + \delta_V V + \delta_R R$$

$$E'(t) = \frac{\beta_S I_S + \beta_A I_A}{\bar{N}} S + (1 - \epsilon) \frac{\beta_S I_S + \beta_A I_A}{\bar{N}} V - (\mu + \delta_E) E$$

$$I'_S(t) = p \delta_E E - (\mu + \alpha_S) I_S$$

$$I'_A(t) = (1 - p) \delta_E E - (\mu + \alpha_A) I_A$$

$$R'(t) = (1 - \theta) \alpha_S I_S + \alpha_A I_A - (\mu + \delta_R) R$$

$$D'(t) = \theta \alpha_S I_S$$

$$V'(t) = \lambda_V S - (1 - \epsilon) \frac{\beta_S I_S + \beta_A I_A}{\bar{N}} V - (\mu + \delta_V) V$$

$$(1)$$

where $\bar{N}(t) = S(t) + E(t) + I_S(t) + I_A(t) + R(t) + V(t)$ and $N = \bar{N} + D$. Parameters description of system 1 is given in Table 1.

Parameter	Description
μ	Death rate
eta_S	Infection rate between susceptible and symp-
0	tomatic infected
eta_A	Infection rate between susceptible and asymptomatic infected
λ_V	Vaccination rate
δ_V^{-1}	Immunity average time by vaccination
ϵ	Effectivity rate of the vaccination
$\stackrel{\epsilon}{\delta_E^{-1}}$	Average time of the incubation period
p	Proportion of symptomatic individuals
$\begin{matrix}p\\\alpha_S^{-1}\end{matrix}$	Average output time of symptomatic individu-
	als due to death or recovery
heta	Proportion of symptomatic individuals who die
	due to the disease
α_A^{-1}	Recovery average time of asymptomatic individ-
	uals
δ_R^{-1}	Immunity average time by disease

Table 1: Parameters definition of system 1.

3. Parameter fitting

Mathematical models for COVID-19 have shown that the parameters values are not necessarily the same in each country. For this reason, we use data from Mexico city plus the surrounding metropolitan area to estimate some parameter values of system 1. These values will be used to exemplify our results. For the parameter estimation process, we fixed some parameter values according the literature, and then followed a two-stages process: i) before, and ii) after mitigation measures were implemented. In both stages, we used model 1, with no vaccination (λ_V and V=0). For the first stage, we consider the dates from the first day of symptoms onset reported (February 19) until March 23, 2020. For the second stage, we took a month later than mitigation measures were implemented, that is, from March 23 to April 23, 2020, and results are shown in Figure 1. It is important to stress that the second stage is used to partially represent the non-pharmaceutical interventions, which implies a reduction of contact transmission rates. Parameter values are summarized in Table 2, while fixed parameters values are shown in Table 3.

Figure 1 shows the fitting curves for the two time periods. With the obtained parameters, we simulated the evolution of the number of infected individuals starting on February 19, 2020 until July 2022. With these dates, it is possible

Parameter	95% Confidence Interval	Quantile 50
eta_S	[0.6689, 1.191]	0.9303
eta_A	[0.5019, 0.7867]	0.6441
p	[0.06088, 0.2239]	0.1213
ξ	[0.3707, 0.4113]	0.3905

Table 2: Estimated values for some parameters of system 1.

Parameter	Value	References
$\begin{array}{c} \delta_E^{-1} \\ \alpha_S^1 \\ \alpha_S^{-1} \\ \alpha_A^{-1} \\ \delta_R^{-1} \\ \mu^{-1} \end{array}$	5.1 days 5.97 days 10.81 days 1 year 75 years	[16] [4] [4]

Table 3: Fixed parameters values of system 1.

to observe two outbreaks (Figure 2), where the second one is referred to as the second wave of COVID-19. With this scenario, it is possible to evaluate the effect of different vaccination strategies, which we consider to start to be applied on March 2021, which is the time prior to the onset of the second wave.




Figure 1: Fitting curves for the early phase of the COVID-19 outbreak in Mexico City plus the surrounding metropolitan area. The left side shows the outbreak from February 19 to March 23, 2020. The right side shows the outbreak from March 23 to April 23, 2020.

4. Vaccination Model Analysis

In this section, we use the estimated parameters from the previous section to analyze Model (1) and the effect of the vaccine. Some plausible scenarios are presented, depending on the effectiveness of the vaccine, as well as the rate of vaccination.

In the first instance, it has been shown that the interest region of the state variables of the system is positively invariant. This implies that any solution with initial conditions within that region will remain within it.

Now, using the next-generation matrix method [17, 18], the basic reproductive number for system (1) is given by

$$R_V = R_S + R_A \tag{2}$$

with

$$R_S = \frac{p\beta_S \delta_E(\mu + \delta_V + (1 - \epsilon)\lambda_V)}{(\mu + \delta_E)(\mu + \delta_V + \lambda_V)(\mu + \alpha_S + \mu_S + \lambda_T)}$$

$$R_A = \frac{(1 - p)\beta_A \delta_E(\mu + \delta_V + (1 - \epsilon)\lambda_V)}{(\mu + \delta_E)(\mu + \delta_V + \lambda_V)(\mu + \alpha_A + \mu_A)}.$$




Figure 2: Dynamics populations without vaccination process. Here, system 1 is reduced when considering $\lambda_V = \delta_V = 0$, $\epsilon = 1$, and V(0) = 0.

Note that each sum of R_V represents the contribution of the symptomatic and asymptomatic infected, respectively, to the spread of the disease.

Now, following the ideas of Alexander et.al. [19], expression for R_V can be rewritten as

$$R_V = R_0 \left(1 - \frac{\epsilon \lambda_V}{(\mu + \delta_V + \lambda_V)} \right) \tag{3}$$

where R_0 is the basic reproduction number of system without vaccine. Note that $\left(1 - \frac{\epsilon \lambda_V}{(\mu + \delta_V + \lambda_V)}\right) < 1$, Therefore, this factor which saves the parameters corresponding to the application of the vaccine will allow us to modulate the value of R_0 . In the first instance, if $R_0 < 1$, then $R_V < 1$. But, if $R_0 > 1$, we wonder if the application of the vaccine can lower R_V value below 1. In this sense, it is easy to prove that, if

$$\epsilon > \frac{(R_0 - 1)(\mu + \delta_V + \lambda_V)}{R_0 \lambda_V},\tag{4}$$

it is possible to reduce the value of R_V below one, of course with the necessary conditions in terms of vaccination. That is, there is a region in the parameter space in which it is possible to reduce the value of R_V below one, considering adequate efficacy, vaccination rate and duration of the effect of the vaccine.

However, if the inequality (4) is not satisfied, it will not be possible to reduce the value of R_V below 1.

To illustrate the aforementioned, Figure 3 shows the regions where it is possible to reduce the value of R_V . In this case, we set all the system parameters, which are given in table 1 and with $\delta_V = 2/365$, leaving ϵ and λ_V free.




Figure 3: In the shaded region $R_V > 1$ and in the white region $R_V < 1$.

Figure 4b shows the regions where it is possible to reduce the value of R_V . In this case, we set all the system parameters, which are given in table 1 and with δ_V , ϵ and λ_V free.




Figure 4: In the shaded region $R_V > 1$ and in the white region $R_V < 1$.

In the next section, the optimal control theory will be applied to propose optimal vaccination dynamics that minimize the number of cases of symptomatic infection and deaths due to the disease.

5. Optimal Vaccine policies

According to dynamics in equation (1), we modulate the vaccination rate by a time-dependent control signal $u_V(t)$. We add compartment X to count all the vaccine applications of susceptible, exposed, asymptomatic and recovered individuals. This process is modeled by

$$X'(t) = (\lambda_V + u_V(t))(S + E + I_A + R)$$
(5)

and describes the number of applied vaccines at time t.

Consider

$$x(t) := (S, E, I_S, I_A, R, D, V, X)^{\top}(t)$$

and control signal $u_v(\cdot)$. We quantify the cost and reward of a vaccine strategy policy via the penalization functional

$$J(u_V) := \int_0^T a_S I_S + a_d D + \frac{1}{2} c_V u_v^2 ds.$$
 (6)

In other words, we assume in functional J that pandemic cost is proportional to the symptomatic and death reported cases and that a vaccination policy implies quadratic consumption of resources.

Further, since we aim to simulate vaccination policies at different coverage scenarios, we impose the vaccination counter state's final time condition X(T)

$$x(T) = (\cdot, \cdot, \cdot, \cdot, \cdot, X(T))^{\top}, \in \Omega$$

$$X(T) = x_{coverage},$$

$$x_{coverage} \in \{\text{Low}(0.2), \text{Mid}(0.5), \text{High}(0.8)\}.$$
(7)

Thus, given the time horizon T, we impose that the last fraction of vaccinated populations corresponds to 20%, 50% or 80%, and the rest of final states as free. We also impose the path constraint

$$\Phi(x,t) := \kappa I_S(t) < B, \qquad \forall t \in [0,T], \tag{8}$$

to ensure that healthcare services will not be overloaded. Here κ denotes hospitalization rate, and B is the load capacity of a health system.

Given a fixed time horizon and vaccine efficiency, we estimate the constant vaccination rate as the solution of

$$x_{coverage} = 1 - \exp(-\lambda_v T). \tag{9}$$

That is, λ_v denotes the constant rate to cover a fraction $x_{coverage}$ in time horizon T. Thus, according to this vaccination rate, we postulate a policy u_v that modulates vaccination rate according to λ_V as a baseline. That is, optimal vaccination amplifies or attenuates the estimated baseline λ_V in a interval $[\lambda_v^{\min}, \lambda_v^{\max}]$ to optimize functional $J(\cdot)$ —minimizing symptomatic, death reported cases and optimizing resources.

Our objective is minimize the cost functional (6)—over an appropriated functional space—subject to the dynamics in equations (1) and (5), boundary conditions, and the path constrain in (8). That is, we search for vaccination policies

 $u_V(\cdot)$, which solve the following optimal control problem (OCP)

$$\min_{u \in \mathcal{U}} J(u) = \int_{0}^{T} a_{S}I_{S}(s) + a_{d}D(s) + \frac{1}{2}c_{V}u_{v}^{2}(s)ds,$$
s.t.
$$S'(t) = \mu \bar{N} - \frac{\beta_{S}I_{S} + \beta_{A}I_{A}}{\bar{N}}S - (\mu + \lambda_{V} + u_{V}(t))S + \delta_{V}V + \delta_{R}R$$

$$E'(t) = \frac{\beta_{S}I_{S} + \beta_{A}I_{A}}{\bar{N}}S + (1 - \epsilon)\frac{\beta_{S}I_{S} + \beta_{A}I_{A}}{\bar{N}}V - (\mu + \delta_{E})E$$

$$I'_{S}(t) = p\delta_{E}E - (\mu + \alpha_{S})I_{S}$$

$$I'_{A}(t) = (1 - p)\delta_{E}E - (\mu + \alpha_{A})I_{A}$$

$$R'(t) = (1 - \theta)\alpha_{S}I_{S} + \alpha_{A}I_{A} - (\mu + \delta_{R})R$$

$$D'(t) = \theta\alpha_{S}I_{S}$$

$$V'(t) = (\lambda_{V} + u_{V}(t))S - (1 - \epsilon)\frac{\beta_{S}I_{S} + \beta_{A}I_{A}}{\bar{N}}V - (\mu + \delta_{V})V$$

$$X'(t) = (\lambda_{V} + u_{V}(t))(S + E + I_{A} + R)$$

$$S(0) = S_{0}, E(0) = E_{0}, I_{S}(0) = I_{S_{0}},$$

$$I_{A}(0) = I_{A_{0}}, R(0) = R_{0}, D(0) = D_{0},$$

$$V(0) = 0, X(0) = 0, u_{V}(.) \in [u_{\min}, u^{\max}],$$

$$X(T) = x_{coverage}, \kappa I_{S}(t) \leq B, \forall t \in [0, T],$$

$$\bar{N}(t) = S + E + I_{S} + I_{A} + R + V.$$

Next section illustrates our results.

6. Numerical experiments

According to the WHO Strategic Advisory Group of Experts (SAGE) on Immunization Working Group on COVID-19 Vaccines modeling questions presented in [20], our model is capable to explore the following scenarios:

Vaccine profile

Vaccination policies according to different profiles, namely:

- efficiency $\epsilon = \{0.1, 0.2, \cdots 0.9\}$.
- vaccine induced immunity

$$\delta_v^{-1} = \{0.5 \, \text{year}, 1.0 \, \text{year}, \cdots, \text{lifelong} \}.$$

Coverage

We obtained optimal vaccination policies with coverage profiles at

$$x_{coverage} = \{20\%, 50\%, 80\%\}.$$

Time horizon

Plausible scenarios at a different analytic time horizon

$$T = \{1 \text{ year}, 2 \text{ year}, 10 \text{ year}\}.$$

To fix ideas, we display in Figure 5 the counterfactual scenario regarding no intervention, constant vaccination policy (CP), and optimal vaccination policy (OP). Dashed lines denote the prevalence of each class according to dynamics with no intervention. Solid lines represent the prevalence according to controlled dynamics with the optimal or constant vaccination policies. Thus, shaded areas respectively denote the gain in mitigation(orange), health resources (red), saved lives (green), coverage (blue), and cost(olive). Here, opaque colors correspond to a constant vaccination policy while translucent colors are related to the gain according to the optimal policy. For example, in the panel titled "Death," the opaque solid line represents the number of accumulated deaths with a constant vaccination policy. The green opaque shaded area is the number of saved lives regarding to CP. Since the translucent green shade area overlaps the opaque green, we say that optimal vaccination improves the gain of a constant policy. Further, since the cost (see olive color) of the CP is above OP, we also say that optimal vaccination is cheaper.

R0: 1.782592 Rv: 1.782579 OC-Rv: 1.782555




Figure 5: Counterfactual scenario regarding no intervention, constant vaccination policy (CP), and optimal vaccination policy (OP), with vaccination efficiency $\epsilon=0.7$, induced vaccination immunity $\delta_V=300$ days and vaccination base rate $\lambda_V=50k/day$.

In Figure 5, we show a scenario where $\mathcal{R}_0 > 1$. Despite \mathcal{R}_v remains below but close to \mathcal{R}_0 . However, vaccination policies improve the estimated damage.

Vaccination reproductive number \mathcal{R}_v , suggests constant policies according to the mitigation factor

 $\left(1 - \frac{\epsilon \lambda_V}{\mu + \delta_V + \lambda_V}\right).$

Then disease mitigation is strongly related to vaccine efficiency ϵ and vaccination rate λ_v . Further, given a dynamic with not vaccine intervention and $\mathcal{R}_0 > 1$, \mathcal{R}_v suggests a minimal vaccination rate to drive this dynamic to the disease-free state. In particular, this vaccine efficiency would govern the viability of the constant policy.

7. Conclusions

Currently, vaccination is the unique strategy to eradicate COVID-19. However, its competence is restricted to several factors such as its distribution, stocks, politics, vaccination efforts among others. A good distribution or application strategy of these drugs is imperative to manage the available resources, especially in developing countries. In order to design optimal vaccination strategies, a mathematical model has been proposed to describe the transmission dynamics of COVID-19, which also includes vaccination dynamics. Our aim is to provide vaccination policies that minimize reported deaths and optimize resource consumption.

Similar to other articles with the same approach, our model presents a reproductive vaccination number (\mathcal{R}_v) that depends on \mathcal{R}_0 [19]. Here, we can see the importance of the parameters related to vaccination dynamics to reduce \mathcal{R}_v . However, according to our simulation parameters setup, to obtain $\mathcal{R}_v < 1$ we need impractical vaccination rates. This last can be improved when implementing NPIs, which can be modeled by transmission contact rates reduction.

To show our scenario of optimal control strategies, we consider Mexico City as the study scenario. Using the data reported by the onset of symptoms, some parameters were estimated, and others from the literature were set. Our results capture the restriction of health care centers that is, do not overcome the available number of beds. Given a target coverage at final time T, we illustrate that an optimal vaccination strategy reduces the number of fatalities compared to the application of the constant vaccination one.

The present work can be extended in different fronts such as i) the evaluation of the inclusion of NPIs at the same time vaccination implementation takes place; ii) the consequences of applying the vaccination strategies during different phases of an outbreak; iii) the effects of using double vaccination doses; iv) the application of different vaccines to distinct groups of individuals, v) vaccine application with knowledge of the percentage of the population that has resulted positive in a seroprevalence study and vi) to improve the efficiency of the optimal control strategies by including a comorbidity class in the model.

References

- [1] World of Health Organization, "Novel Coronavirus (2019-nCoV)- SITUATION REPORT 1." Link, January 2020.
- [2] World of Health Organization, "Coronavirus disease 2019 (COVID-19) SITUATION REPORT 51." Link, March 2020.
- [3] A. J. Rodriguez-Morales, V. Gallego, J. P. Escalera-Antezana, C. A. Méndez, L. I. Zambrano, C. Franco-Paredes, J. A. Suárez, H. D. Rodriguez-Enciso, G. J. Balbin-Ramon, E. Savio-Larriera, et al., "Covid-19 in latin america: The implications of the first confirmed case in brazil," Travel medicine and infectious disease, 2020.
- [4] M. A. Acuña-Zegarra, M. Santana-Cibrian, and J. X. Velasco-Hernandez, "Modeling behavioral change and COVID-19 containment in Mexico: A trade-off between lockdown and compliance," *Mathematical Biosciences*, vol. 325, p. 108370, 2020.
- [5] L. Wang, J. Li, S. Guo, N. Xie, L. Yao, Y. Cao, S. W. Day, S. C. Howard, J. C. Graff, T. Gu, et al., "Real-time estimation and prediction of mortality caused by covid-19 with patient information based algorithm," Science of the Total Environment, p. 138394, 2020.
- [6] Y. Marimuthu, B. Nagappa, N. Sharma, S. Basu, and K. K. Chopra, "Covid-19 and tuberculosis: A mathematical model based forecasting in delhi, india," *Indian Journal of Tuberculosis*, 2020.
- [7] M. Liu, J. Ning, Y. Du, J. Cao, D. Zhang, J. Wang, and M. Chen, "Modelling the evolution trajectory of covid-19 in wuhan, china: experience and suggestions," *Public health*, 2020.
- [8] U. Ghosh, M. Kamrujjaman, and J. K. Ghosh, "Dynamics of seaigr model with saturated type treatment: A case study of spain covid-19," *Preprints*, 2020.
- [9] D. Calvetti, A. Hoover, J. Rose, and E. Somersalo, "Bayesian dynamical estimation of the parameters of an se (a) ir covid-19 spread model," arXiv preprint arXiv:2005.04365, 2020.
- [10] A. S. Shaikh, I. N. Shaikh, and K. S. Nisar, "A mathematical model of covid-19 using fractional derivative: Outbreak in india with dynamics of transmission and control," 2020.
- [11] E. Asano, L. J. Gross, S. Lenhart, and L. A. Real, "Optimal control of vaccine distribution in a rabies metapopulation model," *Mathematical Biosciences & Engineering*, vol. 5, no. 2, p. 219, 2008.
- [12] H. S. Rodrigues, M. T. T. Monteiro, and D. F. Torres, "Vaccination models and optimal control strategies to dengue," *Mathematical biosciences*, vol. 247, pp. 1–12, 2014.

- [13] J. Tchuenche, S. Khamis, F. Agusto, and S. Mpeshe, "Optimal control and sensitivity analysis of an influenza model with treatment and vaccination," *Acta biotheoretica*, vol. 59, no. 1, pp. 1–28, 2011.
- [14] T. Malik, M. Imran, and R. Jayaraman, "Optimal control with multiple human papillomavirus vaccines," *Journal of Theoretical Biology*, vol. 393, pp. 179–193, 2016.
- [15] M. Jaberi-Douraki and S. M. Moghadas, "Optimal control of vaccination dynamics during an influenza epidemic," *Mathematical Biosciences & Engineering*, vol. 11, no. 5, p. 1045, 2014.
- [16] H. Tian, Y. Liu, Y. Li, C.-H. Wu, B. Chen, M. U. Kraemer, B. Li, J. Cai, B. Xu, Q. Yang, et al., "An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China," Science, vol. 368, no. 6491, pp. 638–642, 2020.
- [17] O. Diekmann, J. A. P. Heesterbeek, and J. A. Metz, "On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations," *Journal of mathematical biology*, vol. 28, no. 4, pp. 365–382, 1990.
- [18] P. Van den Driessche and J. Watmough, "Reproduction numbers and subthreshold endemic equilibria for compartmental models of disease transmission," *Mathematical biosciences*, vol. 180, no. 1-2, pp. 29–48, 2002.
- [19] M. E. Alexander, C. Bowman, S. M. Moghadas, R. Summers, A. B. Gumel, and B. M. Sahai, "A vaccination model for transmission dynamics of influenza," *SIAM Journal on Applied Dynamical Systems*, vol. 3, no. 4, pp. 503–524, 2004.
- [20] World Health Organization, "Strategic Advisory Group of Experts (SAGE) on Working Group on COVID-19 Vaccines: WHO Strategic Advisory Group of Experts (SAGE)." Link, July 2020.